The proportion of samples that could theoretically neutralize pFVIII inhibitors and increase plasma FVIII:C to at least 100% (assuming a recovery rate of 2.0) when treated with an initial clinical dose of 200 U/kg rpFVIII was 15 out of 16 (94%), when calculated according to the Japanese Society on Thrombosis and Hemostasis clinical practice guidelines for hemostatic treatment of congenital hemophilia with inhibitors [25]. This evidence concerns the gene F8 and hemophilia.